P2RY12 and atrial fibrillation: The ENTRUST-AF PCI [11] (Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial randomized 1506 AF-PCI patients to DAT with edoxaban 60 mg once daily plus a P2Y12 inhibitor for 12 months or TAT with a VKA for 1–12 months.